Strongbridge Biopharma (NASDAQ:SBBP) has been given a $14.00 price objective by analysts at Cantor Fitzgerald in a report issued on Wednesday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 67.66% from the company’s current price.
The analysts wrote, “Acquisition of U.S. and Canadian rights to MACRILEN, marks early start to commercialize in rare endocrine disorders.””
Several other research firms also recently commented on SBBP. BidaskClub raised Strongbridge Biopharma from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 11th. Zacks Investment Research downgraded Strongbridge Biopharma from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. ValuEngine downgraded Strongbridge Biopharma from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Strongbridge Biopharma in a report on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $12.81.
Strongbridge Biopharma (NASDAQ:SBBP) last released its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.39) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.46) by $0.07. equities analysts expect that Strongbridge Biopharma will post -2.86 EPS for the current fiscal year.
Large investors have recently made changes to their positions in the company. Bank of New York Mellon Corp bought a new position in shares of Strongbridge Biopharma during the second quarter valued at $331,000. Citigroup Inc. bought a new position in shares of Strongbridge Biopharma during the second quarter valued at $338,000. Lyon Street Capital LLC bought a new position in shares of Strongbridge Biopharma during the third quarter valued at $2,862,000. Northern Trust Corp bought a new position in shares of Strongbridge Biopharma during the second quarter valued at $1,462,000. Finally, TIAA CREF Investment Management LLC bought a new position in shares of Strongbridge Biopharma during the second quarter valued at $449,000. 63.96% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3142661/strongbridge-biopharma-sbbp-pt-set-at-14-00-by-cantor-fitzgerald.html.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.